Impact of adherence to statins on coronary artery disease in primary prevention

British Journal of Clinical Pharmacology

Volumn 63, Issue 6, 2007, Pages 698-708

  Bouchard, Marie Hélène ^a   Dragomir, Alice ^a   Blais, Lucie ^a   Bérard, Anick ^a   Pilon, Danielle ^b   Perreault, Sylvie ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Adherence to medical regimen; Coronary artery disease; Statins

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN;

ADULT; AGE; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA BASE; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SOCIAL STATUS;

CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; PRIMARY HEALTH CARE; QUEBEC; RISK FACTORS;

EID: 34248585037     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02828.x     Document Type: Article

References (46)

1. Fondation des maladies du Coeur du Canada. Le Fardeau Croissant des Maladies Cardiovasculaires et des Accidents Vasculaires Cérébraux au Canada, 2003. Report no. 1-89624-32-4. Ottawa : Heart and Stroke Foundation of Canada 2003.
2. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 : 1837 47.
3. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 0 00 men and women from The Copenhagen City Heart Study. Eur Heart J 2002 23 : 620 6.
4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lana F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 364 (9438 937 52.
5. Lloyd-Jones DM, Wilson PW, Larson MG, Leip R, Beiser A, D'Agostino RB, Cleeman JI, Levy D. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med 2003 163 : 1966 72.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 335 : 1001 9.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 (8934 1383 9.
8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 339 : 1349 57.
9. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 333 : 1301 7.
10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 (9326 7 22.
11. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 279 : 1615 22.
12. Sever PS, Poulter NR, Dahlöf B, Wedel H. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOTT-LLA). Am J Cardiol 2005 96 : 39F 44F.
13. Colhoum HM, Betteridge DJ, Durrington PN, Hitman GA, Neil AW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004 364 : 685 96.
14. Larosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJP, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 352 : 1425 35.
15. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. Results from the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol 2005 46 : 1405 10.
16. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003 326 : 1423.
17. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002 288 : 462 7.
18. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002 288 : 455 61.
19. WHO. International Classification of Diseases. Manual of the International Statistical Classification of Diseases, Injuries, and Cause of Death, 9th edn. Publication no PHS 80-1260. Geneva : World Health Organization 1977.
20. Canada: Supply and Services. Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures, 2nd edn. Ottawa : Statistics Canada Health Division 1986.
21. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004 57 : 131 41.
22. Tamblyn R, Reid T, Mayo N, McLeod P, Churchill-Smith M. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000 53 : 183 94.
23. Régie de l'Assurance Maladie. Liste Des Médicaments Québec Canada, 15th edn. Ministère de la Santé, Québec, 2003.
24. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995 48 : 999 1009.
25. Monfared A, Rahme E, LeLorier J. Accuracy of ICD-9 Diagnosis Code '410' to Identify Episodes of Hospitalizations for Acute Myocardial Infarction in RAMQ. First Canadian Therapeutics Congress 2004. Halifax, Canada 2004.
26. Lubin J, Gail M. Biased selection of controls for case control analyses of cohort studies. Biometrics 1984 40 : 63 75.
27. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005 5 : 5.
28. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989 79 : 340 9.
29. Greenland S. Basic methods for sensitivity analysis of biases. Int J Epidemiol 1996 25 : 1107 16.
30. Jones P, Kafonet S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. Am J Cardiol 1998 81 : 582 7.
31. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000 101 : 207 13.
32. Robets WC. The role of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997 80 : 106 7.
33. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 16 : 434 44.
34. Middleton A, Fuat A. Achieving lipid goals in real life: the DISCOVERY-UK Study. Br J Cardiol 2006 13 : 72 6.
35. Foley KA, Simpson RJ Jr., Crouse JR 3rd., Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003 92 : 79 81.
36. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002 360 : 1623 30.
37. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005 46 : 1405 10.
38. Zhou Z, Rahme E, Abrahamowicz M, Tu JV, Eisenberg MJ, Humphries K, Austin PC, Pilote L. Effectiveness of statins for secondary prevention in elderly after acute myocardial infarction: an evaluation of class effect. CMAJ 2005 172 : 1187 94.
39. Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005 28 : 595 9.
40. Kim YS, Sunwoo S, Lee HR, Lee KM, Park YW, Shin HC, Kim CH, Kim DH, Kim BS, Cha HS, Hub BY. Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf 2002 11 : 593 600.
41. McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med 1997 157 : 1921 9.
42. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980 303 : 1038 41.
43. Lam J. Lignes Directrices Pratiques Quant au Traitement Antiplaquettaire, Vol. 2004. Le Groupe de Travail Sur la Thrombose Du Canada, Montréal, 2000.
44. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994 1 : 333 9.
45. Rouleau JL, Talajic M, Sussex B, Potvin L, Warnica W, Davies RF, Gardner M, Stewart D, Plante S, Dupuis R, Lauzon C, Ferguson J, Mikes E, Balnozan V, Savard P. Myocardial infarction patients in the 1990s - their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. J Am Coll Cardiol 1996 27 : 1119 27.
46. LaRosa JC, He J, Vupputuri S. Effect of statins risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999 282 : 2340 6.